Introduction: The aim of this paper is to present new approach for nicotine dependence treatment with Cytisine (Tabex) and to compare it to the dosage regimen, prescribed by the manufacturer.
Material and Methods: 209 patients - smokers intended to quit smoking are divided randomly into two groups. Smokers in the first group are treated with Tabex according to the dosage scheme prescribed by the manufacturer. Patients in the second group are treated according to a new scheme: they stopped smoking from the beginning of the treatment and took 1 tablet of Tabex three times daily. Their treatment with Tabex continued at a dose of one tablet twice a day after the tenth day till 30th day; after 30th day – a maintenance dose of 1 tablet daily for up to 3 months. Both groups of patients were followed-up for one year.
Results and Discussion: The analysis shows that the new approach gives us better results in the tenth day, more sustainable results (after first year).
The observed incidence of adverse events was lower compared to patients treated with dose offered to us by the manufacturer. Despite the lower dose of cytisine, the new scheme is more effective as a nicotine replacement therapy.
Prof. Dr. Bilal BİLGİN